A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT05498428. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).
Study identification
- NCT ID
- NCT05498428
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 520 participants
Conditions and interventions
Conditions
Interventions
- Amivantamab Drug
- Lazertinib Drug
- Carboplatin Drug
- Pemetrexed Drug
- Direct Oral Anticoagulant (DOAC) Drug
- Low Molecular Weight Heparin (LMWH) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 10, 2022
- Primary completion
- Aug 16, 2027
- Completion
- Aug 17, 2028
- Last update posted
- Aug 27, 2026
2022 – 2028
United States locations
- U.S. sites
- 26
- U.S. states
- 14
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California at San Diego | La Jolla | California | 92093 | Recruiting |
| University of California Irvine | Orange | California | 92868 | Recruiting |
| Stanford Cancer Institute | Stanford | California | 94305 | Recruiting |
| Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital | Washington D.C. | District of Columbia | 20016 | Recruiting |
| Baptist Lynn Cancer Institute | Boca Raton | Florida | 33486 | Completed |
| Mount Sinai Medical Center | Miami Beach | Florida | 33140 | Recruiting |
| AdventHealth | Orlando | Florida | 32804 | Recruiting |
| H. Lee Moffitt Cancer & Research Institute | Tampa | Florida | 33612 | Completed |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | Recruiting |
| Sidney Kimmel Cancer Center - Bayview Campus | Baltimore | Maryland | 21224 | Recruiting |
| Boston Medical Center | Boston | Massachusetts | 02118 | Recruiting |
| Washington University School Of Medicine | St Louis | Missouri | 63110 | Recruiting |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | Recruiting |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | Recruiting |
| Hematology-Oncology Associates of CNY | East Syracuse | New York | 13057 | Completed |
| Novant Health 1 | Charlotte | North Carolina | 28204 | Completed |
| Novant Health | Winston-Salem | North Carolina | 27106 | Completed |
| Cleveland Clinic 1 | Cleveland | Ohio | 44111 | Completed |
| Cleveland Clinic | Cleveland | Ohio | 44195 | Completed |
| Cleveland Clinic 2 | Mayfield Heights | Ohio | 44124 | Completed |
| Cleveland Clinic 3 | Warrensville Heights | Ohio | 44122 | Completed |
| The Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | Completed |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | Recruiting |
| Providence Regional Cancer Partnership | Everett | Washington | 98201 | Completed |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | Completed |
| Swedish Cancer Institute | Seattle | Washington | 98104 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 84 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05498428, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05498428 live on ClinicalTrials.gov.